Project ACTT is speeding up cancer testing for targeted treatment selection during the pandemic through a minimally invasive circulating tumor (ctDNA) DNA test. The test, which requires a blood sample, is available as an alternative to some surgical tissue biopsies for patients with advanced lung, breast, or colorectal cancer.
At Canexia Health, we make high-quality cancer genomic information accessible and affordable with our clinically-validated assays, informatics, and support.
Only a small percentage of cancer patients receive genomic biomarker testing that could match them with targeted treatments demonstrated to improve outcomes. We pair the latest advances in oncology with machine learning to provide cancer professionals with the insights needed to make targeted treatment decisions for their patients.
A minimally invasive option for biopsy, Follow It can also be used to monitor cancer progression or investigate treatment resistance.
Rapid, cost-effective, and clinically actionable, Fusions allows you the flexibility to isolate and interrogate relevant fusions.
Tailor treatment decisions based on somatic mutations in your patient’s tumor.
Make more informed treatment decisions by using detailed results for therapeutic recommendations and expertly curated clinical trials information provided in our comprehensive reporting software.
Conduct world-leading mutation assays for cancer patients, right from your laboratory. Our cloud-based analytics platform allows partner labs access to our proprietary informatics software suite covering the full stack of molecular and computational quality assurance, genome analytics, mutation interpretation, and report generation.
“We have found the FIND-IT assay to be a reliable, quick and cost-effective tool for identifying driver mutations in fixed tissue samples from across Australia. This has had direct implications for identifying patients suitable for targeted therapies, especially those with lung cancer, colorectal cancer and melanoma. However, the scope of the test is such that there is also interest in the panel for patients with a variety of other cancers, including breast and endometrial cancers.” Professor Graeme Suthers, Sonic Genetics
May 4, 2021
Microsatellites are short, repeating DNA segments that can play a major role in studying cancers.
April 20, 2021
Precision medicine instruments produce incredible amounts of data, sometimes measured in terabytes or even petabytes.
March 11, 2021
If we are to minimize the now well-documented burdens of COVID-19 on cancer patients, governments must support innovations that improve their outcomes and cut through the healthcare roadblocks posed by the pandemic.
Contact us today to learn about our end-to-end solution, from mutation identification to auto-generated clinical reports.